🦠 Age-Based HPV Dosing Schedule Simulator

Ages 9–14 — First Dose Primes a Strong Response

Younger immune systems mount higher, faster antibody responses to HPV vaccine antigens.

• 9–14: Recommended start age (ACIP two-dose window)
• ~2×: Peak titer vs adults (higher in younger cohort)
• 2: Doses needed (0 and 6–12 month schedule)
• >99%: Seroconversion rate (after full series)

Why younger immune systems respond harder

Thymic output is higher before puberty, boosting naive B-cell priming.

Non-inferiority trials justified dropping dose three for this age group.

The two-dose interval

A 6–12 month gap between doses matures a durable antibody response.

Public health impact

Two doses simplify delivery and raise completion rates in schools.

Ages 9–14 — Second Dose Locks In Protection

Dose two triggers a memory B-cell recall response, driving titers to their peak.

• 6–12 mo: Interval to dose 2 (minimum 5 months)
• ≥: Final titer vs 3-dose adult (non-inferior or higher)
• 2: Doses total (series complete)
• 10+ yrs: Duration of protection (long-term follow-up data)

Recall response kinetics

Memory B cells from dose one expand rapidly after dose two.

Two-dose titers in adolescents match or beat three-dose adult titers.

No third dose needed

Trials showed added doses gave no meaningful extra protection here.

Long-term durability

Follow-up studies show titers stay well above protective thresholds.

Ages 15+ — First Dose Starts From a Lower Baseline

Immune priming weakens with age, so a single dose leaves titers comparatively low.

• 15+: Recommended start age (ACIP three-dose window)
• ~50%: Baseline titer vs teens (lower after dose 1)
• 3: Doses needed (0, 1–2, 6 month schedule)
• Declining: Thymic output (post-puberty involution)

Age-related immune decline

Thymic involution after puberty slows naive B-cell recruitment.

This gap is why regulators require a third dose past age 15.

Single-dose titers fall short

One dose alone does not reach the two-dose adolescent benchmark.

Schedule design implication

A shorter first interval front-loads early partial protection.

Ages 15+ — Second Dose Raises Titers Further

A second dose given 1–2 months later boosts titers to an intermediate level.

• 1–2 mo: Interval to dose 2 (shorter than teen gap)
• ~65%: Titer after dose 2 (of final target level)
• 2: Doses given so far (of 3 required)
• 6 mo: Gap before dose 3 (from first dose)

Partial recall response

Second dose recalls memory cells but titers still trail teens.

Stopping here would leave protection below the target threshold.

Why timing matters

Spacing doses too closely blunts the strength of the recall.

Bridging to dose three

A longer final interval lets affinity maturation continue.

Ages 15+ — Third Dose Reaches Equivalent Protection

The third dose closes the gap, bringing older recipients to teen-level titers.

• 6 mo: Interval to dose 3 (from first dose)
• ≈100%: Final titer (matches 2-dose teen level)
• 3: Doses total (series complete)
• 10+ yrs: Duration of protection (comparable to teens)

Equivalence achieved

Third-dose titers in adults reach parity with two-dose teens.

Same endpoint, different path — age sets the dose count needed.

Clinical bottom line

Vaccinate early when possible — fewer doses, same protection.

Catch-up guidance

Anyone who started late should still finish the full series.